Pyrazoles

"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.

Descriptor ID	D011720
MeSH Number(s)	D03.383.129.539
Concept/Terms	Pyrazoles Pyrazoles

Below are MeSH descriptors whose meaning is more general than "Pyrazoles".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Pyrazoles [D03.383.129.539]

Below are MeSH descriptors whose meaning is related to "Pyrazoles".

Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.

Bar chart showing 63 publications over 22 distinct years, with a maximum of 10 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2001	0	1	1
2005	0	1	1
2006	0	2	2
2007	0	1	1
2008	1	2	3
2009	0	1	1
2010	2	0	2
2011	3	1	4
2012	1	1	2
2013	1	3	4
2014	0	3	3
2015	2	1	3
2017	3	0	3
2018	3	2	5
2019	2	0	2
2020	5	5	10
2021	1	1	2
2022	1	3	4
2023	0	1	1
2024	3	2	5
2025	1	2	3

Below are the most recent publications written about "Pyrazoles" by people in Profiles.

Sharma S, Raju S, Verma SK, Verma R, Thakur PK, Sharath Kumar KS. Pyrazoles: A Master Key to Tackle Multidrug-Resistant Acinetobacter baumannii and Its Structure Activity Relationship Studies. Chem Biol Drug Des. 2025 Mar; 105(3):e70092.

View in: PubMed
Arowosegbe A, Guo Z, Vanderleeden E, Derr AG, Wang JP. Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats. J Autoimmun. 2025 Feb; 151:103358.

View in: PubMed
Wang Y, Fu Q, Sha S, Yoon S. Interferon inhibitors increase rAAV production in HEK293 cells. J Biotechnol. 2025 Mar; 399:9-18.

View in: PubMed
Deligiannidis KM, Bullock A, Nandy I, Dunbar J, Lasser R, Witte M, Leclair B, Wald J. Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):337-344.

View in: PubMed
Meltzer-Brody S, Gerbasi ME, Mak C, Toubouti Y, Smith S, Roskell N, Tan R, Chen SS, Deligiannidis KM. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression. J Med Econ. 2024 Jan-Dec; 27(1):582-595.

View in: PubMed
O'Callaghan L, Chertavian E, Johnson SJ, Ferries E, Deligiannidis KM. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. J Med Econ. 2024 Jan-Dec; 27(1):492-505.

View in: PubMed
Clayton AH, Suthoff E, Jain R, Kosinski M, Fridman M, Deligiannidis KM, Meltzer-Brody S, Chen SY, Gervitz L, Huang MY, Trivedi M, Bonthapally V. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials. J Affect Disord. 2024 04 15; 351:904-914.

View in: PubMed
Kim EJ, Reusch DB, Anthony H, Schmidt B, Corey K, Degar B, Huang JT. Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib. Br J Dermatol. 2024 01 23; 190(2):283-284.

View in: PubMed
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023 09 01; 180(9):668-675.

View in: PubMed
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.

View in: PubMed

People

Explore

Similar Concepts

Top Journals